Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EWTX Edgewise Therapeutics	$13.84 -0.2%	$14.35	$10.60 ▼ $38.12	$1.46B	0.25	1.19 million shs	487,087 shs
QGEN Qiagen	$48.13 -0.9%	$45.37	$37.63 ▼ $49.30	$10.70B	0.68	1.22 million shs	2.42 million shs
ROIV Roivant Sciences	$11.36 -1.8%	$11.11	$8.73 ▼ $13.06	$7.72B	1.15	5.76 million shs	5.08 million shs
SRPT Sarepta Therapeutics	$18.17 -4.7%	$30.98	$16.88 ▼ $154.13	$1.79B	0.45	2.25 million shs	3.08 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EWTX Edgewise Therapeutics	0.00%	+6.83%	-10.25%	+21.19%	-35.69%
QGEN Qiagen	0.00%	-0.43%	+1.58%	+14.66%	+20.66%
ROIV Roivant Sciences	0.00%	+4.75%	-0.96%	+15.21%	+0.98%
SRPT Sarepta Therapeutics	0.00%	-0.25%	-51.30%	-64.39%	-87.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EWTX Edgewise Therapeutics	1.4859 of 5 stars	3.4	0.0	0.0	0.0	1.9	2.5	0.0
QGEN QIAGEN	3.5769 of 5 stars	1.2	4.0	1.7	4.5	1.5	1.7	1.3
ROIV Roivant Sciences	2.8285 of 5 stars	3.6	3.0	0.0	0.0	2.9	2.5	0.0
SRPT Sarepta Therapeutics	4.7155 of 5 stars	4.2	2.0	0.0	4.2	2.4	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EWTX Edgewise Therapeutics	2.80	Moderate Buy	$40.00	189.02% Upside
QGEN Qiagen	2.30	Hold	$49.40	2.64% Upside
ROIV Roivant Sciences	3.25	Buy	$16.50	45.25% Upside
SRPT Sarepta Therapeutics	2.44	Hold	$58.54	222.19% Upside

Current Analyst Ratings Breakdown

Latest EWTX, QGEN, ROIV, and SRPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ROIV Roivant Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$19.00
7/10/2025	SRPT Sarepta Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $28.00
6/30/2025	EWTX Edgewise Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/26/2025	QGEN Qiagen	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $53.00
6/25/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
6/24/2025	QGEN Qiagen	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$55.00
6/20/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$123.00 ➝ $45.00
6/20/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/18/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
6/18/2025	SRPT Sarepta Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$85.00 ➝ $40.00
6/18/2025	SRPT Sarepta Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.84 per share	N/A
QGEN Qiagen	$2.00B	5.34	$3.20 per share	15.02	$16.05 per share	3.00
ROIV Roivant Sciences	$29.05M	265.84	N/A	N/A	$7.45 per share	1.52
SRPT Sarepta Therapeutics	$1.90B	0.94	$2.44 per share	7.46	$15.99 per share	1.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EWTX Edgewise Therapeutics	-$133.81M	-$1.55	N/A	N/A	N/A	N/A	-30.95%	-29.45%	8/6/2025 (Estimated)
QGEN Qiagen	$83.59M	$0.40	120.67	19.57	2.45	4.68%	14.61%	8.80%	8/5/2025 (Estimated)
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/6/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.66	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)

Latest EWTX, QGEN, ROIV, and SRPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	N/A	N/A	N/A	$530.66 million	N/A
8/5/2025	Q2 2025	QGEN Qiagen	$0.60	N/A	N/A	N/A	$523.97 million	N/A
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/8/2025	Q1 2025	EWTX Edgewise Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
5/7/2025	Q1 2025	QGEN Qiagen	$0.50	$0.55	+$0.05	$0.41	$465.66 million	$483.46 million
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
QGEN Qiagen	$0.25	0.52%	N/A	62.50%	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest EWTX, QGEN, ROIV, and SRPT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/1/2025	QGEN Qiagen		$0.25	0.52%	7/2/2025	7/3/2025	7/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EWTX Edgewise Therapeutics	N/A	20.99	20.99
QGEN QIAGEN	0.40	3.37	2.83
ROIV Roivant Sciences	N/A	33.47	33.47
SRPT Sarepta Therapeutics	1.00	4.02	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EWTX Edgewise Therapeutics	N/A
QGEN Qiagen	70.00%
ROIV Roivant Sciences	64.76%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
EWTX Edgewise Therapeutics	23.20%
QGEN Qiagen	9.00%
ROIV Roivant Sciences	7.90%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EWTX Edgewise Therapeutics	60	105.20 million	80.79 million	Optionable
QGEN Qiagen	5,765	222.29 million	202.29 million	Optionable
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable

EWTX, QGEN, ROIV, and SRPT Headlines

Recent News About These Companies

Sarepta Therapeutics (NASDAQ:SRPT) Given New $28.00 Price Target at JPMorgan Chase & Co.

July 13 at 2:57 AM | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

July 12 at 10:00 AM | prnewswire.com

Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

July 12 at 9:53 AM | theglobeandmail.com

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit

July 12 at 8:26 AM | prnewswire.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Banque Pictet & Cie SA

July 12 at 5:08 AM | marketbeat.com

Principal Financial Group Inc. Trims Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

July 12 at 3:35 AM | marketbeat.com

Lost Money on Sarepta Therapeutics, Inc.(SRPT)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

July 11 at 4:22 PM | globenewswire.com

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 11 at 4:00 PM | globenewswire.com

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

July 11 at 10:41 AM | globenewswire.com

Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

July 11 at 9:00 AM | prnewswire.com

Zacks Research Has Optimistic Outlook of SRPT Q2 Earnings

July 11 at 6:42 AM | marketbeat.com

Sarepta Therapeutics Inc. Research & Ratings | SRPT | Barron's

July 11 at 5:10 AM | barrons.com

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

July 10 at 8:40 PM | globenewswire.com

Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights – SRPT

July 10 at 4:55 PM | globenewswire.com

Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $28.00 at JPMorgan Chase & Co.

July 10 at 4:29 PM | marketbeat.com

Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The ...

July 10 at 10:48 AM | gurufocus.com

Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights - SRPT

July 10 at 9:00 AM | prnewswire.com

INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, ...

July 10 at 8:21 AM | gurufocus.com

INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT

July 10 at 7:44 AM | globenewswire.com

Sarepta Therapeutics: Overcoming Setbacks with Promising Long-term Potential

July 10 at 6:57 AM | tipranks.com

SRPT - Sarepta Therapeutics Inc Ownership - Morningstar

July 9, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX, QGEN, ROIV, and SRPT Company Descriptions

Edgewise Therapeutics NASDAQ:EWTX

$13.84 -0.03 (-0.22%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$13.36 -0.48 (-3.50%)

As of 07/11/2025 04:11 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Qiagen NYSE:QGEN

$48.13 -0.42 (-0.87%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$48.12 -0.01 (-0.02%)

As of 07/11/2025 05:23 PM Eastern

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Roivant Sciences NASDAQ:ROIV

$11.36 -0.21 (-1.82%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$11.36 0.00 (-0.04%)

As of 07/11/2025 07:59 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Sarepta Therapeutics NASDAQ:SRPT

$18.17 -0.90 (-4.72%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$18.16 -0.01 (-0.08%)

As of 07/11/2025 07:50 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time